Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema

Inclusion Criteria: * adult patients with uveitis or retinal vasculitis with unilateral or bilateral macular oedema * with macular thickness \> 250 micra using OCT * visual acuity at least 20/200 * with stable treatment with oral prednisone at least during 3 months, either oral ciclosporin or other immunomodulator to treat intraocular inflammatory disease * patient that can follow study's requirements * patient who consents to participate Exclusion Criteria: * presence of corneal or crystalline opacity preventing observation of fundus of eye * patients requiring ocular surgery in next 3 months * one-eyed * pregnancy and child breastfeeding * previous history of glaucoma * on treatment woth an experimental ocular drug * previous thromboembolism or receiving oral anticoagulant treatment * vitrectomy * patients with proved tractional macular pathology associated to macular oedema